Mechanistically, these cells appear to contribute to fibrosis through the Wnt4‐PDGFRα pathway, suggesting a potential therapeutic avenue for HF.[116] These findings highlight the role of CD34+ cells and Sca1+ cells in cardiac fibrosis and suggest their potential therapeutic avenues for HF treatment. This evidence concerns the gene CD34 and hydrops fetalis.